Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy.

A 35-year-old multipara presented at 17 weeks gestation with a right breast mass and bloody nipple discharge. On examination, she had a palpable 10 · 9 cm right breast mass and a 4 cm right axillary lymph node. A core biopsy revealed invasive ductal carcinoma. The tumor was negative for estrogen, progesterone, and HER2 receptors—a triple-negative phenotype. Limited staging with liver ultrasound and magnetic resonance imaging of Tand L-spine were unrevealing for metastases. After multidisciplinary discussions with high-risk maternal and fetal specialists and oncologists, at 24 weeks gestation, the patient received four cycles of dose-dense doxorubicin and cyclophosphamide (AC), with growth factor [granulocyte colony-stimulating factor (G-CSF)] support between each cycle with dramatic response [1]. Serial fetal ultrasounds during chemotherapy indicated normal fetal growth and development. Subsequently, the patient started weekly paclitaxel—also with Annals of Oncology letters to the editor